Delaware | 000-52008 | 54-1560050 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. | Results of Operations and Financial Condition |
Item 9.01. | Financial Statements and Exhibits |
(d) | Exhibits. |
Exhibit | Description | |
99.1 | Press Release dated August 12, 2014 by Luna Innovations Incorporated. |
Luna Innovations Incorporated | ||
By: | /s/ Talfourd H. Kemper, Jr. | |
Talfourd H. Kemper, Jr. Vice President and General Counsel |
Exhibit | Description | |
99.1 | Press Release dated August 12, 2014 by Luna Innovations Incorporated. |
• | Total revenues grew to $5.2 million in the second quarter of 2014 compared to $4.8 million in the second quarter of 2013. |
• | Technology development revenue increased by 15%, to $3.2 million, for the second quarter of 2014, from $2.8 million for the second quarter of 2013. |
• | Products and licensing revenue was $2.0 million for the second quarter of 2014 flat relative to the second quarter of 2013, but up 12% compared to the first quarter of 2014. |
• | Gross profit for the second quarter of 2014 improved to $2.0 million, or 38% of total revenues, compared to $1.8 million, or 37% of total revenues, for the second quarter of 2013. |
• | Selling, general and administrative expenses decreased by 14% to $2.5 million, or 47% of total revenues for the second quarter of 2014, from $2.9 million, or 60% of total revenues, for the second quarter of 2013. |
• | Total operating expenses decreased to $3.0 million, or 56% of total revenues, for the second quarter of 2014 from $3.5 million, or 73% of total revenue for the second quarter of 2013. |
• | Adjusted EBITDA improved to $(0.5) million in the second quarter of 2014 from $(1.1) million in the second quarter of 2013. |
• | Net loss attributable to common stockholders for the second quarter of 2014 improved to $0.9 million from $1.0 million for the second quarter of 2013. |
• | Cash and cash equivalents totaled $14.7 million at June 30, 2014, as compared to $7.8 million at December 31, 2013 and $10.9 million at March 31, 2014. During the second quarter of 2014 the company received the second $6.0 million installment from Intuitive Surgical related to the sale of the company's medical shape sensing business. |
• | Total revenue increased by 9% to $9.7 million for the six months ended June 30, 2014 compared to $8.9 million for the six months ended June 30, 2013. |
• | Technology development revenues increased by 8%, from $5.4 million for the six months ended June 30, 2013 to $5.9 million for the six months ended June 30, 2014. |
• | Products and licensing revenue increased by 9%, from $3.5 million for the six months ended June 30, 2013 to $3.8 million for the six months ended June 30, 2014. |
• | Gross profit for the six months ended June 30, 2014 increased by 20%, to $3.5 million, compared to a gross profit of $3.0 million for the six months ended June 30, 2013. Gross margin percentages increased to 36% of total revenue for the first six months of 2014 from 33% of total revenue for the first six months of 2013. |
• | Selling, general and administrative expenses decreased to $5.2 million, representing 54% of total revenues for the six months ended June 30, 2014 compared to $5.5 million or 62% of total revenues for the six months ended June 30, 2013. |
• | Total operating expenses decreased to $6.5 million, or 67% of total revenues, for the six months ended June 30, 2014, from $6.9 million or 78% of total revenues, for the six months ended June 30, 2013. |
• | Adjusted EBITDA improved to $(2.0) million for the six months ended June 30, 2014 from $(2.7) million for the six months ended June 30, 2013. |
• | Net income attributable to common stockholders improved to $7.6 million for the six months ended June 30, 2014, compared to net income attributable to common stockholders of $1.8 million for the six months ended June 30, 2013 largely the result of a net after-tax gain of $9.4 million realized on the sale of the company’s medical shape sensing business in the first quarter of 2014. |
June 30, 2014 | December 31, 2013 | ||||||
(unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 14,674,973 | $ | 7,778,541 | |||
Accounts receivable, net | 5,481,642 | 5,408,281 | |||||
Inventory, net | 3,314,608 | 3,346,177 | |||||
Prepaid expenses | 582,934 | 708,974 | |||||
Other current assets | 70,207 | 70,208 | |||||
Total current assets | 24,124,364 | 17,312,181 | |||||
Property and equipment, net | 1,939,607 | 2,060,709 | |||||
Intangible assets, net | 188,816 | 288,475 | |||||
Other assets | 5,126 | 42,710 | |||||
Total assets | $ | 26,257,913 | $ | 19,704,075 | |||
Liabilities and stockholders’ equity | |||||||
Liabilities : | |||||||
Current Liabilities | |||||||
Current portion of long term debt obligation | $ | 1,375,000 | $ | 1,500,000 | |||
Current portion of capital lease obligation | 68,640 | 66,617 | |||||
Accounts payable | 1,520,093 | 1,401,764 | |||||
Accrued liabilities | 2,781,931 | 3,546,585 | |||||
Deferred credits | 391,712 | 691,424 | |||||
Total current liabilities | 6,137,376 | 7,206,390 | |||||
Long-term debt obligation | — | 625,000 | |||||
Long-term lease obligation | 75,474 | 110,307 | |||||
Total liabilities | 6,212,850 | 7,941,697 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Preferred stock | 1,322 | 1,322 | |||||
Common stock, par value $ 0.001, 100,000,000 shares authorized, 15,003,901 and 14,527,335 shares issued at June 30, 2014 and December 31, 2013, respectively | 15,299 | 14,842 | |||||
Less treasury stock at cost, 22,725 shares at June 30, 2014 and zero at December 31, 2013 | (32,221 | ) | — | ||||
Additional paid-in capital | 63,503,505 | 62,756,571 | |||||
Accumulated deficit | (43,442,842 | ) | (51,010,357 | ) | |||
Total stockholders’ equity | 20,045,063 | 11,762,378 | |||||
Total liabilities and stockholders’ equity | $ | 26,257,913 | $ | 19,704,075 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||
(unaudited) | (unaudited) | ||||||||||||||
Revenue: | |||||||||||||||
Technology development revenue | $ | 3,219,435 | $ | 2,807,296 | $ | 5,894,887 | $ | 5,434,537 | |||||||
Products and licensing revenue | 2,008,862 | $ | 2,023,668 | 3,805,291 | 3,501,795 | ||||||||||
Total revenue | 5,228,297 | 4,830,964 | 9,700,178 | 8,936,332 | |||||||||||
Cost of revenue: | |||||||||||||||
Technology development costs | 2,388,801 | 2,209,158 | 4,413,956 | 4,394,072 | |||||||||||
Products and license costs | 851,490 | 844,441 | 1,746,130 | 1,583,130 | |||||||||||
Total cost of revenue | 3,240,291 | 3,053,599 | 6,160,086 | 5,977,202 | |||||||||||
Gross Profit | 1,988,006 | 1,777,365 | 3,540,092 | 2,959,130 | |||||||||||
Operating expense: | |||||||||||||||
Selling, general and administrative | 2,466,626 | 2,875,461 | 5,221,704 | 5,538,569 | |||||||||||
Research, development and engineering | 484,509 | 641,790 | 1,233,663 | 1,401,781 | |||||||||||
Total operating expense | 2,951,135 | 3,517,251 | 6,455,367 | 6,940,350 | |||||||||||
Operating loss | (963,129 | ) | (1,739,886 | ) | (2,915,275 | ) | (3,981,220 | ) | |||||||
Other income/(expense): | |||||||||||||||
Other income, net | 29,325 | 94,990 | 111,431 | 193,144 | |||||||||||
Interest expense | (27,302 | ) | (49,781 | ) | (59,667 | ) | (107,960 | ) | |||||||
Total other income | 2,023 | 45,209 | 51,764 | 85,184 | |||||||||||
Loss from continuing operations before income taxes | (961,106 | ) | (1,694,677 | ) | (2,863,511 | ) | (3,896,036 | ) | |||||||
Income tax (benefit)/expense | (375,983 | ) | (659,341 | ) | (1,145,173 | ) | (1,541,768 | ) | |||||||
Loss from continuing operations | (585,123 | ) | (1,035,336 | ) | (1,718,338 | ) | (2,354,268 | ) | |||||||
Gain on sale, net of $0.4 million, $0.3 million, $1.3 million and $1.3 million of related income taxes, respectively | (330,716 | ) | (364,338 | ) | 9,370,799 | 3,682,159 | |||||||||
Operating (loss)/ income from discontinued operations, net of $0.0, $0.3 million, $0.0 million and $0.3 million related income tax, respectively | — | 447,592 | (28,076 | ) | 505,624 | ||||||||||
Discontinued operations, net of tax | (330,716 | ) | 83,254 | 9,342,723 | 4,187,783 | ||||||||||
Net (loss)/income | (915,839 | ) | (952,082 | ) | 7,624,385 | 1,833,515 | |||||||||
Preferred stock dividend | 27,334 | 26,366 | 56,870 | 49,995 | |||||||||||
Net (loss)/income attributable to common stockholders | $ | (943,173 | ) | $ | (978,448 | ) | $ | 7,567,515 | $ | 1,783,520 | |||||
Net loss per share from continuing operations: | |||||||||||||||
Basic | $ | (0.04 | ) | $ | (0.07 | ) | $ | (0.12 | ) | $ | (0.17 | ) | |||
Diluted | $ | (0.04 | ) | $ | (0.07 | ) | $ | (0.12 | ) | $ | (0.17 | ) | |||
Net (loss)/income per share from discontinued operations: | |||||||||||||||
Basic | $ | (0.02 | ) | $ | 0.01 | $ | 0.63 | $ | 0.29 | ||||||
Diluted | $ | (0.02 | ) | $ | — | $ | 0.54 | $ | 0.25 | ||||||
Net (loss)/income per share attributable to common stockholders: | |||||||||||||||
Basic | $ | (0.06 | ) | $ | (0.07 | ) | $ | 0.51 | $ | 0.13 | |||||
Diluted | $ | (0.06 | ) | $ | (0.07 | ) | $ | 0.44 | $ | 0.11 | |||||
Weighted average common shares and common equivalent shares outstanding: | |||||||||||||||
Basic | 14,817,084 | 14,362,494 | 14,722,474 | 14,206,598 | |||||||||||
Diluted | 14,817,084 | 16,723,796 | 17,201,639 | 16,558,246 |
Six months ended June 30, | |||||||
2014 | 2013 | ||||||
(unaudited) | |||||||
Cash used in operating activities | |||||||
Net income | $ | 7,624,385 | $ | 1,833,515 | |||
Adjustments to reconcile net income (loss) to net cash used in operating activities | |||||||
Depreciation and amortization | 336,564 | 489,244 | |||||
Share-based compensation | 488,593 | 618,084 | |||||
Warrant expense | — | — | |||||
Gain on sale of discontinued operations, net of income taxes | (9,370,799 | ) | (3,868,114 | ) | |||
Allowance for doubtful accounts or bad debt expense | — | 124,810 | |||||
Tax benefit from utilization of net operating loss carryforward | (1,163,301 | ) | (1,021,538 | ) | |||
Change in assets and liabilities: | |||||||
Accounts receivable | (73,857 | ) | 834,122 | ||||
Inventory | (6,796 | ) | (309,217 | ) | |||
Other current assets | 72,141 | (40,647 | ) | ||||
Other assets | 37,584 | 72,584 | |||||
Accounts payable and accrued expenses | (761,149 | ) | 174,916 | ||||
Deferred credits | (299,712 | ) | (221,553 | ) | |||
Net cash used in operating activities | (3,116,347 | ) | (1,313,794 | ) | |||
Cash flows used in investing activities | |||||||
Acquisition of property and equipment | (135,136 | ) | (69,108 | ) | |||
Intangible property costs | (138,118 | ) | (145,858 | ) | |||
Proceeds from sale of discontinued operations, net of fees | 10,927,268 | 4,522,460 | |||||
Net cash provided by/(used in) investing activities | 10,654,014 | 4,307,494 | |||||
Cash flows used in financing activities | |||||||
Payments on capital lease obligations | (32,810 | ) | (26,641 | ) | |||
Payment of debt obligations | (750,000 | ) | (625,000 | ) | |||
Purchase of treasury stock | (32,221 | ) | — | ||||
Proceeds from the exercise of options and warrants | 173,796 | 60,349 | |||||
Net cash used in financing activities | (641,235 | ) | (591,292 | ) | |||
Net increase in cash or cash equivalents | 6,896,432 | 2,402,408 | |||||
Cash and cash equivalents, beginning of period | 7,778,541 | 6,340,461 | |||||
Cash and cash equivalents, end of period | $ | 14,674,973 | $ | 8,742,869 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||
(unaudited) | (unaudited) | ||||||||||||||
Net income/(loss) | $ | (915,839 | ) | $ | (952,082 | ) | $ | 7,624,385 | $ | 1,833,515 | |||||
Less (loss)/income from discontinued operations, net of income taxes | (330,716 | ) | 83,254 | 9,342,723 | 4,187,783 | ||||||||||
Loss from continuing operations | (585,123 | ) | (1,035,336 | ) | (1,718,338 | ) | (2,354,268 | ) | |||||||
Interest expense | 27,302 | 49,781 | 59,667 | 107,960 | |||||||||||
Tax (benefit) expense | (375,983 | ) | (659,341 | ) | (1,145,173 | ) | (1,541,768 | ) | |||||||
Depreciation and amortization | 134,259 | 260,979 | 336,564 | 489,244 | |||||||||||
EBITDA | (799,545 | ) | (1,383,917 | ) | (2,467,280 | ) | (3,298,832 | ) | |||||||
Share-based compensation | 257,654 | 304,568 | 488,593 | 618,084 | |||||||||||
Adjusted EBITDA | $ | (541,891 | ) | $ | (1,079,349 | ) | $ | (1,978,687 | ) | $ | (2,680,748 | ) |